Category:Investigational Drugs
From Glioblastoma Treatments
Investigational Drugs
This category includes drugs that are currently being studied in clinical trials or are under investigation for the treatment of glioblastoma. These medications may not yet be FDA-approved for brain cancer treatment.
| Drug Name | Overall Survival without PBT | Overall Survival with PBT | Progression-Free Survival without PBT | Progression-Free Survival with PBT | Usefulness Rating | toxicity level | Toxicity Explanation | |
|---|---|---|---|---|---|---|---|---|
| Sativex | Sativex (Nabiximols) | Not specified | The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone | Not specified | Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival | 4 | 2 | The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country. |
| Valcyte | Valganciclovir (Valcyte) | Median survival with standard treatment: 17.4 months | Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27% | Not specified | Not directly specified; improvements noted in selected patient analyses | 3 | 2 | The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma. |
Loading comments...
Standard Treatments Alternative Treatment Centers and Clinics Integrative Oncologist
